Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	<u></u>
ATTORNEY'S DKT NO.	APPLICATION NO.
003300-831	09/970,793
APPLICANT	
Nils Ove GUSTAVSSON	N et al.
FILING DATE	GROUP
October 5, 2001	1615
T .	

STATE SAF			U.S. PATENT DOCUMENTS:		en en deur des	(海公療) (政
	U.S. Patent		T			始基。
Examiner Initials	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document		Date of Publication (MM-DD-YYYY)	
1	5,981,719	· .	Woiszwillo et al.	 	11/199	
	5,849,884]	Woiszwillo et al.		12/199	
	5,776,885		Orsolini et al.		07/199	
	5,753,234		Lee et al.		05/199	
	5,667,808		Johnson <i>et al.</i>		09/199	
	5,654,010		Johnson <i>et al.</i>		08/1997	
	5,622,657		Takeda <i>et al</i> .		04/199	
	5,578,709		Woiszwillo et al.		11/1996	
	5,470,582		Supersaxo <i>et al</i> .		11/1995	
	5,455,342		Redding, Jr.		10/199	
	5,407,609		Tice et al.	T:		5
	4,713,249		Schröder		12/198	
	4,389,330		Tice et al.		06/198	
	3,881,991		'Kurimotor <i>et al.</i>		05/197	
	3,737,337		Schnoring <i>et al.</i> 06/1973			
-010	3,691,090		Kitajima <i>et al.</i>		09/1972	
FOREIGN PATENT DOCUMENTS Foreign Patent Document						
Examiner Initials	Number	Kind Code (if known)	Country		ite of Publication MM-DD-YYYY)	Translation
_ (*\V	WO 99/20253	A1	PCT		04/1999	Yes n
	WO 99/00425	A1	PCT		01/1999	
	W0 97/14408	A1	PCT		04/1997	
	WO 96/10042	A1 ·	PCT		04/1996	
	WO 94/12158	A1	РСТ		06/1995	
	WO 93/21008	A1	РСТ		10/1993	
	EP 0 330 180	B2	EPO		03/1999	
	EP 0 688 429	B1	EPO		02/1998	
	EP 0 540 582	B1	EPO		08/1994	
	EP 0 213 303	A2	EPO		03/1987	
MA	WO 90/13780	A1	PCT		11/1990	
			TENT LITERATURE DOCUMEN		And the second of the second	2 F 25 F 2
Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	<u> </u>
ATTORNEY'S DKT NO.	APPLICATION NO.
003300-831	09/970,793
APPLICANT	
Nils Ove GUSTAVSSON	et al. ·
FILING DATE	GROUP
October 5, 2001	1615

	Artursson et al., "Characterization of Polyacryl Starch Microparticles as Carriers for Proteins and Drugs," Journal of Pharmaceutical Sciences, Vol. 73, No. 11, pp. 1507-1513, (1984)				
	Franssen et al., "A Novel Preparation Method for Polymeric Microparticles Without the Use of Organic Solvents," International Journal of Pharmaceutics, Vol. 168, pp. 1-7 (1998)				
	Fu et al., "Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres" Pharmaceutical Research, Vol. 17, No. 1, pp. 100-106 (2000)				
	Laakso et al., "Biodegradable Microspheres IV: Factors Affecting the Distribution and Degradation of Polyacryl Starch Microparticles," Journal of Pharmaceutical Sciences, Vol. 75, No. 10, pp. 962-967 (1986)				
	Laakso et al., "Biodegradable Microspheres X: Some Properties of Polyacryl Starch Microparticles Prepared from Acrylic Acid-Esterified Starch," Journal of Pharmaceutical Sciences, Vol. 76, No. 12, pp. 935-939 (1987)				
	Schröder, "Crystallized Carbohydrate Spheres as a Slow Release Matrix for Biologically Active Substances," Biomaterials, Vol. 5, pp. 100-104 (1984)				
	Schröder, "Crystallized Carbohydrate Spheres for Slow Release and Targeting," Enzymology, Vol. 112, No. 9, pp. 116-128 (1985)				
	Stenekes et al., "The Preparation of Dextran Microspheres in an All-Aqueous System: Effect of the Formulation Parameters on Particle Characteristics," <i>Pharmaceutical Research</i> , Vol. 15, No. 4 pp. 557-561 (1998)				
	Stjärnkvist <i>et al.</i> , "Biodegradable Microspheres XIII: Properties of the Crosslinking Chains in Polyacryl Starch Microparticles," <i>Journal of Pharmaceutical Sciences</i> , Vol. 78, No. 1, pp. 52-56 (1989)				
	Agersø et al., "Plasma Concentration of hGH and anti-hGH Antibodies After Subcutaneous Administration of hGH for 3 Weeks to Immunosuppressed Pigs," J. Pharmacol Toxicol No. 41 pp. 1-8 (1999)				
	Johnson et al., "A Month-Long effect From a Single Injection of Microencapsulated Human Growth Hormone," Nature Medicine, Vol. 2, No. 7 pp. 795-799 (1996)				
	Putney, "Encapsulation of Proteins for Improved Delivery," Current Opinion in <i>Chemical Biology</i> , Nol. 2, pp. 548-552 (1998)				
AX	"Clean Package Insert," Nutropin Depot (somatropin(rDNA origin) for injectable suspension), Genentech, Inc., 1 DNA Way, South San Francisco, CA 940-4990, pp. 1-6 (December 13, 1999)				
 					
_					
Examiner Signature	Date Considered 4/13/0				
	/				